正常促性腺激素性无排卵且克罗米芬失败女性中换用促性腺激素与继续使用克罗米芬(伴或不伴宫腔内人工授精)的长期结局:析因随机临床试验随访研究
本研究对M-ovin试验中666名正常促性腺激素性无排卵且克罗米芬失败女性进行随访,比较换用促性腺激素与继续克罗米芬、以及加用宫腔内人工授精与否的长期结局。中位随访8年,促性腺激素组活产率83.7% vs 克罗米芬组78.9%(RR 1.06,95%CI 0.96-1.17),宫腔内人工授精组82.3% vs intercourse组80.2%(RR 1.03,95%CI 0.93-1.13)。
要点
- 正常促性腺激素性无排卵且克罗米芬失败女性中约五分之四可获得至少一次活产。
- 换用促性腺激素与继续克罗米芬相比,长期妊娠结局差异小。
- 加用宫腔内人工授精未显著增加活产率。
核心结论
- 正常促性腺激素性无排卵且克罗米芬失败女性有高机会获得至少一次活产;就妊娠率而言,初始换用促性腺激素与继续克罗米芬的长期差异小。
研究设计与样本
- 对M-ovin析因随机临床试验(2009-2015年,666名正常促性腺激素性无排卵且6个周期克罗米芬失败女性)的随访研究,研究人群包括所有参与M-ovin试验的女性。
主要发现
- 中位随访8年,促性腺激素组184人中154人(83.7%)活产 vs 克罗米芬组190人中150人(78.9%),RR 1.06(95%CI 0.96-1.17)。
- 第二次活产:促性腺激素组184人中85人(49.0%) vs 克罗米芬组190人中85人(44.7%),RR 1.03(95%CI 0.83-1.29)。
- 第三次活产:促性腺激素组184人中6人(3.3%) vs 克罗米芬组190人中14人(7.4%)。
- 双胎:促性腺激素组12例 vs 克罗米芬组11例。
- 宫腔内人工授精组192人中158人(82.3%)获得首次活产 vs intercourse组182人中146人(80.2%),RR 1.03(95%CI 0.93-1.13),差值2.13%(95%CI -5.95至10.21)。
关键数值与推荐
- 主要结局为累积活产,次要结局包括临床妊娠、多胎妊娠、流产、死产、异位妊娠、生育治疗、新生儿结局和妊娠并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 57%的女性有完整随访结果。
- 185名女性未回复问卷,102名女性因联系方式缺失未被联系。
- 5名女性未开始原始试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the long-term outcomes after allocation to use of gonadotrophins versus clomiphene citrate (CC) with or without IUI in women with normogonadotropic anovulation and clomiphene failure? SUMMARY ANSWER: About four in five women with normogonadotropic anovulation and CC failure had a live birth, with no evidence of a difference in pregnancy outcomes between the allocated groups. WHAT IS KNOWN ALREADY: CC has long been used as first line treatment for ovulation induction in women with normogonadotropic anovulation. Between 2009 and 2015, a two-by-two factorial multicentre randomized clinical trial in 666 women with normogonadotropic anovulation and six cycles of CC failure was performed (M-ovin trial). This study compared a switch to gonadotrophins with continued treatment with CC for another six cycles, with or without IUI within 8 months. Switching to gonadotrophins increased the chance of conception leading to live birth by 11% over continued treatment with CC after six failed ovulatory cycles, at a cost of €15 258 per additional live birth. The addition of IUI did not significantly increase live birth rates. STUDY DESIGN, SIZE, DURATION: In order to investigate the long-term outcomes of switching to gonadotrophins versus continuing treatment with CC, and undergoing IUI versus continuing with intercourse, we conducted a follow-up study. The study population comprised all women who participated in the M-ovin trial. PARTICIPANTS/MATERIALS, SETTING, METHODS: The participating women were asked to complete a web-based questionnaire. The primary outcome of this study was cumulative live birth. Secondary outcomes included clinical pregnancies, multiple pregnancies, miscarriage, stillbirth, ectopic pregnancy, fertility treatments, neonatal outcomes and pregnancy complications. MAIN RESULTS AND THE ROLE OF CHANCE: We approached 564 women (85%), of whom 374 (66%) responded (184 allocated to gonadotrophins; 190 to CC). After a median follow-up time of 8 years, 154 women in the gonadotrophin group had a live birth (83.7%) versus 150 women in the CC group (78.9%) (relative risk (RR) 1.06, 95% CI 0.96-1.17). A second live birth occurred in 85 of 184 women (49.0%) in the gonadotrophin group and in 85 of 190 women (44.7%) in the CC group (RR 1.03, 95% CI 0.83-1.29). Women allocated to gonadotrophins had a third live birth in 6 of 184 women (3.3%) and women allocated to CC had a third live birth in 14 of 190 women (7.4%). There were respectively 12 and 11 twins in the gonadotrophin and CC groups. The use of fertility treatments in the follow-up period was comparable between both groups. In the IUI group, a first live birth occurred in 158 of 192 women (82.3%) and while in the intercourse group, 146 of 182 women (80.2%) reached at least one live birth (RR: 1.03 95% CI 0.93-1.13; 2.13%, 95% CI -5.95, 10.21). LIMITATIONS, REASONS FOR CAUTION: We have complete follow-up results for 57% of the women.There were 185 women who did not respond to the questionnaire, while 102 women had not been approached due to missing contact details. Five women had not started the original trial. WIDER IMPLICATIONS OF THE FINDINGS: Women with normogonadotropic anovulation and CC failure have a high chance of reaching at least one live birth. In terms of pregnancy rates, the long-term differences between initially switching to gonadotrophins are small compared to continuing treatment with CC. STUDY FUNDING/COMPETING INTEREST(S): The original study received funding from the Dutch Organization for Health Research and Development (ZonMw number: 80-82310-97-12067). A.H. reports consultancy for development and implementation of a lifestyle App, MyFertiCoach, developed by Ferring Pharmaceutical Company. M.G. receives unrestricted grants for scientific research and education from Ferring, Merck and Guerbet. B.W.M. is supported by an NHMRC Investigatorgrant (GNT1176437). B.W.M. reports consultancy for ObsEva and Merck and travel support from Merck. All other authors have nothing to declare. TRIAL REGISTRATION NUMBER: This follow-up study was registered in the OSF Register, https://osf.io/pf24m. The original M-ovin trial was registered in the Netherlands Trial Register, number NTR1449.
引用
- Bordewijk EM, Jannink TI, Weiss NS, et al. Long-term outcomes of switching to gonadotrophins versus continuing with clomiphene citrate, with or without intrauterine insemination, in women with normogonadotropic anovulation and clomiphene failure: follow-up study of a factorial randomized clinical trial. Hum Reprod. 2023. PMID: 36622200. doi:10.1093/humrep/deac268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。